Главная › Рак молочной железы › Мэриленд › Baltimore
Клинические исследования Рак молочной железы в городе Baltimore, MD
47 исследований по теме Рак молочной железы ищут участников в центрах в городе Baltimore и поблизости (в радиусе около 30 миль). Откройте исследование, чтобы узнать критерии участия и контакты исследовательской группы.
Официальный текст исследования (на английском)
Ищете участников для исследования? Разместите его вверху страницы — $99 на 30 дней →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Набор участниковФаза 3
- Mercy Medical Center, Baltimore
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набор участниковНаблюдательное исследованиеПриглашаются здоровые добровольцы
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- и еще 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Набор участниковФаза 2
- Johns Hopkins University, Baltimore
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Набор участниковФаза 3
- Maryland Proton Treatment Center, Baltimore
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Набор участниковФаза 2
- Maryland Proton Treatment Center, Baltimore
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Набор участниковФаза 3
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Набор участниковФаза 3
- Greenebaum Comprehensive Cancer Center ( Site 0036), Baltimore
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Набор участниковФаза 3
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Annapolis · 22 миль отсюда
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Набор участниковФаза 1
- United Theranostics, Glen Burnie · 9 миль отсюда
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Набор участниковФаза 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Набор участниковФаза 3
- Saint Agnes Hospital, Clinical Research Center, Baltimore
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Набор участниковФаза 3
- Mercy Medical Center, Baltimore
- Ascension St. Agnes Hospital, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Набор участниковФаза 1/2
- Research Site, Baltimore
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Набор участниковФаза 1/2
- Maryland Oncology Hematology - Annapolis, Annapolis · 22 миль отсюда
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Набор участниковФаза 3
- Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore
Cardiometabolic Screening Program
Набор участников
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Набор участниковФаза 2
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Набор участниковФаза 3
- University of Maryland, Baltimore
- Velocity Clinical Research, Annapolis · 22 миль отсюда
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Набор участниковФаза 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Mercy Medical Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- и еще 8
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Набор участниковФаза 2
- The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Набор участниковФаза 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Набор участниковФаза 2/3
- Local Institution - 1035, Baltimore
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Набор участниковФаза 3
- Maryland Oncology Hematology, Annapolis · 22 миль отсюда
E-Mindfulness Approaches for Living After Breast Cancer
Набор участниковФаза 3
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- и еще 7
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Набор участниковФаза 2
- The John Hopkins Hospital, Baltimore
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Набор участниковФаза 2
- Sidney Kimmel Comprehensive Cancer Center, Baltimore
EXoPERT EMERALD Clinical Study
Набор участниковНаблюдательное исследованиеПриглашаются здоровые добровольцы
- John Hopkins University, Baltimore
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Набор участниковФаза 3
- Johns Hopkins Kimmel Cancer Center, Baltimore
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Набор участниковФаза 1
- Johns Hopkins University, Baltimore
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Набор участниковФаза 1
- Advanced Molecular Imaging and Therapy, Glen Burnie · 9 миль отсюда
- United Theranostics - Chesapeake, Glen Burnie · 9 миль отсюда
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Набор участниковФаза 1
- United Theranostics, Glen Burnie · 9 миль отсюда
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Набор участниковФаза 3
- Mfsmc-Hjwci, Baltimore
- Maryland Oncology Hematology P.A., Annapolis · 22 миль отсюда
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Набор участниковФаза 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- Saint Agnes Hospital, Baltimore
- и еще 7
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набор участниковНаблюдательное исследование
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- UM Saint Joseph Medical Center, Towson · 8 миль отсюда
- и еще 1
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
Набор участников
- Sidney Kimmel Comprehensive Cancer Center, the Avon Foundation Breast Center at Johns Hopkins, Baltimore
- Johns Hopkins Bayview, Baltimore
- Johns Hopkins Kimmel Cancer Center at Greenspring Station, Lutherville · 9 миль отсюда
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
Набор участников
- UMMC, Baltimore
- Baltimore Washington Medical Center, Glen Burnie · 9 миль отсюда
- Upper Chesapeake Health, Bel Air · 22 миль отсюда
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Набор участниковФаза 1
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Набор участниковНаблюдательное исследование
- Weinberg Center at Mercy, Baltimore
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- и еще 3
Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors
Набор участников
- Breast Evaluation and Treatment Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Study in Patients With Breast Cancer Leptomeningeal Metastasis
Набор участниковНаблюдательное исследование
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набор участниковНаблюдательное исследование
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · 8 миль отсюда
The Cancer of the Pancreas Screening-5 CAPS5)Study
Набор участниковФаза 3
- Johns Hopkins Hospital, Baltimore
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Набор участниковФаза 3
- UM Upper Chesapeake Medical Center, Bel Air · 22 миль отсюда
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Набор участниковНаблюдательное исследование
- Mercy Medical Center, Baltimore
- Johns Hopkins Hospital, Baltimore
- Luminis Health Center for Cancer & Blood Disorders, Annapolis · 22 миль отсюда
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Набор участниковФаза 2
- University of Maryland Medical Center (UMMC), Baltimore
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Набор участниковФаза 1/2
- Johns Hopkins, Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Набор участниковФаза 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Исследования Рак молочной железы в других городах
- New York City, NY134 исследований
- Houston, TX126 исследований
- Boston, MA111 исследований
- Nashville, TN80 исследований
- Los Angeles, CA72 исследований
- Edison, NJ68 исследований
- St. Louis, MO64 исследований
- Durham, NC63 исследований
- Queens, NY63 исследований
- Chicago, IL58 исследований
- Philadelphia, PA56 исследований
- Dallas, TX55 исследований
Другие исследования в городе Baltimore
- Немелкоклеточный рак легкого60 исследований
- Рак простаты43 исследований
- Рак легких40 исследований
- Рак (все виды)37 исследований
- Колоректальный рак31 исследование
- Рак поджелудочной железы31 исследование
- Метастатический рак28 исследований
- Ожирение25 исследований
- Сердечная недостаточность24 исследований
- Рак мочевого пузыря24 исследований
- Инсульт22 исследований
- Рак яичников22 исследований
Источник: ClinicalTrials.gov, данные получены 5 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.